Share on StockTwits

Auspex Pharmaceuticals (NASDAQ:ASPX) major shareholder Ventures Vii Lp Cmea sold 29,600 shares of the company’s stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $22.03, for a total transaction of $652,088.00. Following the completion of the transaction, the insider now directly owns 3,731,012 shares of the company’s stock, valued at approximately $82,194,194. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Auspex Pharmaceuticals (NASDAQ:ASPX) traded up 3.42% during mid-day trading on Friday, hitting $22.99. 115,013 shares of the company’s stock traded hands. Auspex Pharmaceuticals has a 52-week low of $13.25 and a 52-week high of $35.78. The stock’s 50-day moving average is $19.96 and its 200-day moving average is $22.91. The company’s market cap is $527.4 million.

Auspex Pharmaceuticals (NASDAQ:ASPX) last announced its earnings results on Thursday, August 7th. The company reported ($0.45) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.33) by $0.12. Analysts expect that Auspex Pharmaceuticals will post $-2.03 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Stifel Nicolaus raised their price target on shares of Auspex Pharmaceuticals from $39.00 to $40.00 in a research note on Friday, August 8th. They now have a “buy” rating on the stock. Analysts at Robert W. Baird raised their price target on shares of Auspex Pharmaceuticals from $34.00 to $42.00 in a research note on Friday, July 11th. They now have an “outperform” rating on the stock.

Auspex Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of medicines for the treatment of orphan diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.